Sagimet Biosciences Inc. | Small-cap | Healthcare
$9.83
17.58%
| Sagimet Biosciences Stock Comparison:
Sagimet Biosciences vs VertexSagimet Biosciences vs RegeneronSagimet Biosciences vs Alpha Tau MedicalSagimet Biosciences vs CartesianSagimet Biosciences vs Foghorn TherapeuticsSagimet Biosciences vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -54.5M
Net Income -45.6M
EPS (Diluted) -$1.45

Balance Sheet Metrics

Total Assets 160.3M
Total Liabilities 4.5M
Shareholders Equity 155.8M
Debt to Equity 0.03

Cash Flow Metrics

Operating Cash Flow -40.3M
Free Cash Flow -42.4M

Revenue & Profitability Trend

Sagimet Biosciences Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 0 2.0M 0 0 0
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 54.5M 32.7M 31.1M 23.7M 11.4M
Operating Income -54.5M -30.7M -31.1M -23.7M -11.4M
Pre-tax Income -45.6M -27.9M -30.5M -24.4M -11.4M
Income Tax - - - - -
Net Income -45.6M -27.9M -30.5M -24.4M -11.4M
EPS (Diluted) -$1.45 -$2.66 -$1.38 -$1.10 -$0.51

Income Statement Trend

Sagimet Biosciences Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 152.8M 96.6M 32.8M 58.7M 68.7M
Non-Current Assets 7.5M 73.0K 239.0K 369.0K 221.0K
Total Assets 160.3M 96.7M 33.0M 59.0M 69.0M
Liabilities
Current Liabilities 4.5M 5.7M 5.3M 2.4M 1.9M
Non-Current Liabilities 0 0 214.7M 214.9M 203.0M
Total Liabilities 4.5M 5.7M 220.0M 217.3M 204.9M
Equity
Total Shareholders Equity 155.8M 91.1M -187.0M -158.3M -135.9M

Balance Sheet Composition

Sagimet Biosciences Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -45.6M -27.9M -30.5M -24.4M -11.4M
Operating Cash Flow -40.3M -22.9M -28.6M -22.5M -10.6M
Investing Activities
Capital Expenditures - - - - 20.0K
Investing Cash Flow -61.7M 12.6M -32.0M 0 20.0K
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 104.7M 86.2M -85.0K 9.6M 68.9M
Free Cash Flow -42.4M -23.8M -24.5M -21.7M -10.4M

Cash Flow Trend

Sagimet Biosciences Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -6.67
Forward P/E -2.35
Price to Book 1.94
PEG Ratio -2.35

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -34.72%
Return on Assets -24.05%

Financial Health

Current Ratio 20.34
Debt to Equity 0.03

Per Share Data

EPS (TTM) -$1.78
Book Value per Share $4.32
Revenue per Share $0.00

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
sgmt 269.2M -6.67 1.94 -34.72% 0.00% 0.03
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alpha Tau Medical 245.6M - 3.63 -47.95% 0.00% 21.83
Cartesian 250.0M 1.81 -12.32 1,138.25% -112.11% -0.65
Foghorn Therapeutics 272.6M - -5.07 190.26% 0.00% -0.57

Financial data is updated regularly. All figures are in the company's reporting currency.